2023
MDS Chapter
Wong EY, Rose MG. Update on MDS for Cancer: Principles & Practice of Oncology, 12th edition, 2023.Commentaries, Editorials and LettersCML Chapter
Wong EY, Rose MG. Update on CML for Cancer: Principles & Practice of Oncology, 12th edition, 2023.Commentaries, Editorials and LettersCLL Chapter
Wong EY, Rose MG. Update on CLL for Cancer: Principles & Practice of Oncology, 12th edition, 2023.Commentaries, Editorials and Letters
2020
Disorders of Red Blood Cells
Wong E, Rose MG, Berliner N. Disorders of red blood cells. In: Wing E. and Shiffman F. eds. Cesil Essentials of Medicine, 10th ed. Elsevier 2020.ChaptersClinical Disorders of Granulocytes and Monocytes
Wong E, Rose MG and Berliner N. Clinical Disorders of Granulocytes and Monocytes. In: Wing E. and Schiffman F. eds. Cecil Essentials of Medicine, 10th ed. Elsevier 2020.Chapters
2019
Multicenter phase II trial of RRx-001 in previously treated SCLC.
Morgensztern D, Rose M, Morris J, Ma P, Brzezniak C, Zeman K, Padmanabhan A, Hirth J, Spira A, Wong E, Padda S, Waqar S. Multicenter phase II trial of RRx-001 in previously treated SCLC. Journal Of Clinical Oncology 2019, 37: e20104-e20104. DOI: 10.1200/jco.2019.37.15_suppl.e20104.Peer-Reviewed Original ResearchSmall cell lung cancerRRx-001Partial responseStable diseaseOverall survivalPrior linesCommon treatment-emergent adverse eventsSingle-arm phase II studyArm phase II studyMulticenter phase II trialTreatment-emergent adverse eventsPhase II studyPhase II trialPlatinum-resistant diseaseCell lung cancerOverall response rateTreat populationII trialPrimary endpointAdverse eventsEtoposide chemotherapyII studyComplete responsePlatinum therapyLung cancer
2018
Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study)
Zwicker J, Schlechter B, Stopa J, Liebman H, Aggarwal A, Caughey T, Bauer K, Kuemmerle N, Wong E, Wun T, Mclaughlin M, Puligandla M, Neuberg D, Furie B, Flaumenhaft R. Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study). Blood 2018, 132: 985. DOI: 10.1182/blood-2018-99-114946.Peer-Reviewed Original ResearchVenous thromboembolismDay 56Major hemorrhageAdvanced cancerAntithrombotic efficacyCancer patientsHigh riskThrombus formationD-dimer plasma concentrationIncidence of VTEPlasma D-dimer levelsNon-small cell lungPhase II clinical trialPlatelet-dependent thrombin generationPrevent Venous ThromboembolismPhase II studySecond-line chemotherapySymptomatic pulmonary embolismD-dimer levelsLower extremity DVTPhase II trialMonths of initiationLower extremity ultrasoundSoluble P-selectinInitial human studiesImpact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma
Giri S, Wong E, Rose M, Wadia R, Park L, Justice A, Neparidze N. Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma. Blood 2018, 132: 3162. DOI: 10.1182/blood-2018-99-115633.Peer-Reviewed Original ResearchVeterans Aging Cohort StudyMultiple myelomaEM diseaseUninfected patientsClinical characteristicsLytic lesionsOutcome of MMRisk of MMImpact of HAARTRole of HAARTStage 3 diseaseSymptomatic multiple myelomaTime of diagnosisAggressive clinical courseAging Cohort StudyClinical outcome dataCourse of diseasePlasma cell disordersDurie-Salmon stageVeterans Health AdministrationImpact of HIVSignificant differencesStage 1High rateStage 2QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.
Padda S, Brzezniak C, Waqar S, Wakelee H, Ma P, Rose M, Reid T, Spira A, Wong E, Zeman K, Oronsky B, Abrouk N, Morgensztern D. QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer. Journal Of Clinical Oncology 2018, 36: e20575-e20575. DOI: 10.1200/jco.2018.36.15_suppl.e20575.Peer-Reviewed Original Research
2014
Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient Satisfaction
Neparidze N, Cecchini M, Wong E, Rose M. Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient Satisfaction. Blood 2014, 124: 4857. DOI: 10.1182/blood.v124.21.4857.4857.Peer-Reviewed Original ResearchElectronic medical recordsHematology consultationTimeliness of careE-consultsFace visitsHematology clinicPatient satisfactionProvider satisfactionPatient careAbnormal coagulation profileMajority of patientsComprehensive electronic medical recordsPeripheral blood smearUnnecessary patient visitsNumber of veteransHealthcare delivery methodsVenous thromboembolismMedical chartsCoagulation profileRetrospective reviewAddition patientsPatient preferencesMedical recordsPatient visitsIron indices
2013
Myeloproliferative Neoplasms
Wong EY, Rose MG. Myeloproliferative Neoplasms Chapter. In: Primary Care, eds. Rose MG, DeVita VT, Lawrence TS, Rosenberg S, Oeffinger KC, Schwenk TL, Wender RC. Lippincott Williams & Wilkins, 1st ed. 2013.Chapters
2002
Erythroid Expression of the Human α-Spectrin Gene Promoter Is Mediated by GATA-1- and NF-E2-binding Proteins*
Boulanger L, Sabatino DE, Wong EY, Cline AP, Garrett LJ, Garbarz M, Dhermy D, Bodine DM, Gallagher PG. Erythroid Expression of the Human α-Spectrin Gene Promoter Is Mediated by GATA-1- and NF-E2-binding Proteins*. Journal Of Biological Chemistry 2002, 277: 41563-41570. PMID: 12196550, DOI: 10.1074/jbc.m208184200.Peer-Reviewed Original ResearchMeSH Keywords5' Flanking RegionAnimalsBase SequenceBinding SitesDNA, ComplementaryDNA-Binding ProteinsErythroid Precursor CellsErythroid-Specific DNA-Binding FactorsErythropoiesisGATA1 Transcription FactorHeLa CellsHumansK562 CellsMiceMice, TransgenicMolecular Sequence DataNF-E2 Transcription FactorNF-E2 Transcription Factor, p45 SubunitPromoter Regions, GeneticSpectrinTranscription FactorsConceptsGene promoterGATA-1Reporter genePromoter/reporter plasmidsAlpha-spectrinGel mobility shift assaysErythroid-specific expressionFull promoter activityAlpha-spectrin geneMobility shift assaysErythroid progenitor cellsHuman tissue culture cell linesTissue culture cell linesAdult reticulocytesErythroid promoterNonerythroid tissuesMembrane proteinsLow-level expressionRegulatory elementsShift assaysErythroid expressionCell shapeDNase IErythroid cellsPromoter activity